A Phase 1b/2, Open-label, Multicenter, Dose-escalation and Expansion Trial of Intratumoral SD-101 in Combination With Pembrolizumab in Patients With Metastatic Melanoma or Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma. Save

Date Added
June 13th, 2017
PRO Number
Pro00064826
Researcher
Terrence Day

Silhouette
Keywords
Cancer/Head & Neck, Drug Studies
Summary

This is a phase 1b/2, open-label, multicenter trial designed to look at the safety and efficacy of a study drug called SD 101 when injected into a tumor and used in combination with intravenous (IV) pembrolizumab in subjects with metastatic melanoma or recurrent or metastatic head and neck squamous cell carcinoma (HNSCC). The Medical University of South Carolina will only participate in phase 2 of this study and will include up to 10 subjects. Participation in this study will include up to 40 visits to the research center over approximately 110 weeks.

Institution
MUSC
Recruitment Contact
Lauren Card
843-792-5935
cardl@musc.edu

RNA Biomarkers in the Progression of Oropharyngeal Squamous Cell Carcinoma: A Prospective Non-Randomized Study by the Head and Neck Oncology Group (HNOG) at the Medical University of South Carolina Save

Date Added
January 6th, 2015
PRO Number
Pro00033992
Researcher
Terrence Day

Silhouette
Keywords
Cancer, Cancer/Head & Neck
Summary

This study seeks to assess the evolving biomarkers identifiied in head and neck cancers including smoking related and human papillomavirus related markers and their correlation with clinical outcomes, quality of life, survivorship and cancer control.

Head and neck cancer patients will be offered the opportunity to participate in HeadNOG which includes survey information about cancer diagnosis, signs and symptoms, demographics, cancer site, stage and histology and long term outcomes.

This analysis will then assess RNA/DNA biomarkers and lipid profiles, and their role in the etiopathogenesis, treatment and outcomes for head and neck cancer.

It is the goal of HeadNOG to provide a date resource that results in strategies for personalized care of head and neck cancer patients in South Carolina for the future.

Ultimately, it is hoped that biomarkers will direct patient care and improve quality of life and cancer control.

Institution
MUSC
Recruitment Contact
Terrence Day
843=792-0719
dayt@musc.edu

Phase II Randomized Trial of Transoral Surgical Resection followed by Low-dose or Standard-dose IMRT in Resectable p16+ Locally Advanced Oropharynx Cancer Save

Date Added
July 1st, 2014
PRO Number
Pro00033852
Researcher
Terrence Day

Silhouette
Keywords
Cancer, Cancer/Head & Neck, Surgery
Summary

This study is for adult male and female patients with a virus associated with head and neck cancer. The purpose of this study is to study the effects, good and/or bad of performing surgery through your mouth (what is referred to as transoral surgery) followed by treatment that is selected based on studying your cancer under a microscope by a doctor (called a pathologist), on you and your human papillomavirus associated oropharynx cancer. The study is being done because we think that the results of studying your cancer under the microscope can help us be more careful about how much extra treatment needs to be given after surgery.

Institution
MUSC
Recruitment Contact
Kristina Godwin
843-792-6349
woodrufk@musc.edu

Change_preferences

-- OR --

Create_login